GlassScriptPhysician profile
Thierry Duchatellier
NPI 1619987120
$12,426.79
in general payments reported to CMS, 2019-2025
33 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,000 · 2020: $1,415 · 2021: $2,044 · 2022: $2,693 · 2023: $2,621 · 2024: $1,279 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,194 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,193.89 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,399.74 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Optis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,230.34 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,158.18 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,053.68 | 2019-2024 | Farxiga, Lokelma, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,023.56 | 2019-2025 | |
| Amgen INC. | $915.65 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $913.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $890.29 | 2021-2024 | Verquvo |
| Boston Scientific Corporation | $521.96 | 2020-2023 | Watchman Flx, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $452.99 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $436.13 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $384.84 | 2019-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $373.17 | 2019-2023 | Uptravi, Opsumit |
| Esperion Therapeutics, INC. | $304.52 | 2020-2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $254.10 | 2023-2024 | Inpefa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $182.24 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $153.34 | 2019-2022 | |
| Amarin Pharma, INC. | $112.99 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $96.25 | 2022-2024 | Assure Wcd |
| Bardy Diagnostics, INC. | $81.35 | 2022 | |
| Scpharmaceuticals INC. | $76.39 | 2023-2024 | |
| Gilead Sciences, INC. | $64.65 | 2019 | |
| Daiichi Sankyo INC. | $59.76 | 2020 | |
| Lundbeck LLC | $51.19 | 2019-2020 | |
| Csl Behring | $39.34 | 2020-2021 | |
| Chiesi USA, INC. | $34.82 | 2021 | |
| Medicomp INC | $32.95 | 2023 | Telepatch Cardiac Monitor |
| Philips North America LLC | $26.12 | 2025 | Extended Holter |
| Regeneron Healthcare Solutions, INC. | $22.24 | 2019 | |
| Infobionic, INC | $21.46 | 2019 | |
| Baxter Healthcare | $21.12 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Tris Pharma INC | $19.19 | 2020 | |
| Alnylam Pharmaceuticals INC. | $19.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thierry Duchatellier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.